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Objective: To demonstrate the feasibility and safety of training midlevel healthcare providers (midwives and family nurses) to provide
medical abortion and postabortion contraception in underserved areas in Kyrgyzstan.
Study design: This was an implementation study at four referral facilities and 28 Felsher Obstetric Points in two districts to train their midwives
and family nurses to deliver safe and effective abortion care with co-packaged mifepristone–misoprostol and provide contraceptives
postabortion. The outcome of abortion— complete abortion, incomplete abortion or o-going pregnancy—was the primary end point measured.
An international consultant trained 18 midwives and 14 family nurses (with midwifery diplomas) to provide medical abortion care. Supervising
gynecologists based in the referral centers and study investigators based in Bishkek provided monthly monitoring of services and collection of
patient management forms. A voluntary self-administered questionnaire at the follow-up visit documented women's acceptability of medical
abortion services. All study data were cross-checked and entered into an online data management system for descriptive analysis.
Results: Between August 2014 and September 2015, midwives provided medical abortion to 554 women with a complete abortion rate of
97.8%, of whom 62% chose to use misoprostol at home. No women were lost to follow-up. Nearly all women (99.5%) chose a contraceptive
method postabortion; 61% of women receiving services completed the acceptability form, of whom more than 99% indicated a high level of
satisfaction with the service and would recommend it to a friend.
Conclusion: This study demonstrates that trained Kyrgyz midwives and nurses can provide medical abortion safely and effectively. This
locally generated evidence can be used by the Kyrgyz Ministry of Health to reduce unintended pregnancy and expand safe abortion care to
women in underserved periurban and rural settings.
Implications: Success in scaling up midwife/nurse provision of medical abortion in Kyrgyzstan will require registration of mifepristone–
misoprostol, regulations permanently allowing midwife/nurse provision, strengthened procurement and distribution systems to prevent☆ Ethical approval: The HRP Research Project Review Panel, the WHO Research Ethics Review Committee and the Bioethics Committee of the Kyrgyz
Ministry of Health reviewed and approved the study.
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Research has shown that trained midwives and nurses can
provide medical abortion as safely as trained physicians;
they can help to expand the provider base in resource-poor
settings, thus reducing inequities in access; and they can help
to improve the quality and reduce the costs of safe abortion
care [1–6]. Based on the strength of existing evidence, in
2015, the World Health Organization (WHO) reiterated the
safety of medical abortion provided by midwives, nurses,
and other midlevel providers through recommendations and
guidance on health worker roles in providing safe abortion
care [7].
In 2009, the Kyrgyzstan Ministry of Health requested
WHO and UNFPA support to address the problem of
morbidity and mortality related to unsafe abortion. The
request led to a strategic assessment on prevention and care
for unintended pregnancies conducted in 2011. A strategic
assessment is Stage I of the WHO Strategic Approach to
Strengthening Sexual and Reproductive Health Policies
and Programmes [8]. It is a country-led process that
facilitates a national team to identify and prioritize needs
and potential follow-up actions related to improving sexual
and reproductive health and rights, such as prevention of
unintended pregnancy and unsafe abortion. The approach
provides the foundation for planning, developing and testing
policy and service delivery options (Stage II), and scaling-up
national programs (Stage III). It aims to generate information,
understanding and consensus about sexual and reproductive
health and rights needs as well as a national mandate for
addressing them.
The 2011 strategic assessment found that women in
underserved areas of Kyrgyzstan had limited options for
safely terminating unwanted pregnancies, often involving
travel over long distances to access safe services. One of the
priority recommendations of the assessment was to train
local midwives and nurses to provide medical abortion
in order to extend safe abortion care to women living in
these areas.2. Materials and methods
2.1. Study background
The Kyrgyz Republic gained independence from the
former Soviet Union in 1991. The population of nearly 6million people is young, with a median age of 25; 36% of the
total population live in urban areas and 64% live in rural
areas [9]. The educational level is high, with 96% having
some secondary education [10]. Life expectancy at birth in
2014 was 71 years: 75 years for women and 67 years for men
[10]. The maternal mortality ratio in 2015 was estimated to
be 76 deaths per 100,000 live births [11]. Reliable data on
morbidity and mortality from unsafe abortion in Kyrgyzstan
are unavailable.
Abortion on a woman's request without restriction as to
reason is available in Kyrgyzstan up to 12 weeks’ gestational
age and for economic and social reasons up to 22 weeks.
Under the current law, all abortions must be provided by an
obstetrician–gynecologist in a public or private medical
institution [12]. The Ministry of Health gave temporary
authorization for midwives and family nurses to provide
medical abortion during the research study.
Contraceptivesmade available during the study— condoms,
pills, intrauterine devices (IUDs), Depo-Provera® — reflected
what was affordably available in pharmacies or through
humanitarian assistance. Other contraceptives, such as
subdermal implants, were not included due to their high cost
and irregular availability. Eleven midwives from Suzak District
had been previously trained to insert IUDs; untrainedmidwives/
nurses referred women wanting an IUD to the supervising
gynecologist.
In Kyrgyzstan, midwives must pass a 3-year course in a
medical college with practical skills training at primary care
family medicine centers and maternity hospitals. Midwives
are trained to provide family planning, including hormonal
contraceptives and Depo-Provera®. Training also includes
monitoring of pregnancy, labor management and delivery,
and postpartum care. Family nurse training involves a 2-year
course with practical training in outpatient clinics. The
nursing course covers many of the same topics as for
midwives, excluding management of labor and delivery.
Although not a requirement of the Ministry of Health, all
family nurses that participated in the project also had a
midwifery diploma.
The World Bank and other international organizations
supported implementation of the National Health Care
Reform Programme “Manas” from 1996 to 2000. Manas
focused on strengthening primary healthcare through the
establishment of family medicine centers, family group
practices and Felsher Obstetrics Points (FOPs). FOPs serve
high-risk poor families living in periurban neighborhoods
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postpartum care, emergency obstetric care, information and
counseling on reproductive health, family planning and child
health. FOPs serve catchment areas of 1500–6000 people.
2.2. Study design, ethical approval, informed consent and
liability coverage for midwives
This was an implementation study to demonstrate that
trained midwives and family nurses can provide safe and
effective abortion care with the combination mifepristone–
misoprostol, as recommended by WHO. A total of 32
midwives and family nurses (1 per study site) were trained in
2 referral centers and 14 linked FOPs in Suzak District,
Jalal-Abad Oblast, and 2 referral centers and 14 linked FOPs
in Alamudun District, Chui Oblast.
The HRP Research Project Review Panel, the WHO
Research Ethics Review Committee and the Bioethics
Committee of the Kyrgyz Ministry of Health reviewed and
approved the study. A special Ministry of Health Order
(No. 263, dated 20 May 2013) allowed midwives and nurses
to provide medical abortion in the selected health facilities
during the study.
An international consultant trained all participating
midlevel providers in provision of mifepristone–misoprostol
based on the regimen recommended byWHO [13]. All of them
were provided with Medabon® (a co-packaged mifepristone–
misoprostol product), nonsteroidal anti-inflammatory drugs,
Frautest Express® pregnancy tests (manufactured by
BOLEAR, Ltd., Moscow), contraceptives (pills, condoms,
injectables and IUDs), and mobile cell phones and cell phone
credits (demonstrated successfully in other medical abortion
studies [14,15]) to facilitate follow-up contact with patients.
Information leaflets announcing the services were printed and
distributed in the local communities. The study was conducted
between August 2014 and September 2015.1
A midwife or family nurse provided information on safe
abortion options to all women requesting abortion; the
women could then choose between vacuum aspiration and
medical abortion and whether to receive care from a
midwife/nurse or a gynecologist. Those who opted for
vacuum aspiration and those who opted for medical abortion
from a gynecologist were referred and not included in the
study; they were charged 190 KGS (approx. US$3.00)
for their abortion care according to the official government
price list.
The women who chose medical abortion with a midwife/
nurse were given an informed consent form to sign, as1 The study protocol called for a 9-month recruitment period; however,
due to a lengthy delay in finalizing the study methodology, the medical
abortion intervention had to be suspended from November 2014 due to the
expiration of the first batch of Medabon®. Although a new order of
Medabon® was made well in advance of the expiration date, the company,
Sun Pharmaceutical Ltd., was unable to fill the order for 8 months due to
their involvement in a corporate takeover action and subsequent closure of
production lines. All midwives received refresher training as soon as the
new batch of Medabon® became available in April 2015.required by law, with comprehensive information on the
method. They also gave verbal consent to allow the linkage
of anonymized medical data to a numerically coded,
voluntary acceptability form. All participant information
was coded and individual identifiers removed.
The midwives/nurses provided preabortion counseling,
assessed gestational age2 and eligibility for medical
abortion, provided Medabon® and conducted in-clinic
follow-up in both the referral centers and FOPs. Throughout
the duration of the project, the Medabon® provided by
midwives/nurses was free of charge.
They also gave detailed information during the counsel-
ing process about contraceptive methods (condoms, pills,
IUDs, Depo-Provera®) and their side effects using flip charts
and samples of the methods.
The outcome of the abortion — complete abortion,
incomplete abortion or ongoing pregnancy — was the
primary study end point. The study also documented
participant characteristics, referrals to higher-level care and
acceptance of contraception postabortion. Women who
agreed to do so completed a self-administered questionnaire
on a voluntary basis at the end of the follow-up visit
regarding the acceptability of the medical abortion service.2.3. Study inclusion and exclusion criteria
Study inclusion criteria included the following:
• Woman's desire to have medical abortion managed by
a midwife/nurse;
• Gestational age not more than 63 days, as estimated
by woman's account of last menstrual period, a
gynecological exam and/or ultrasound;
• Woman's willingness to return to the clinic for a
follow-up visit between days 7 and 14;
• Residence within the geographical catchment area
specified for the site;
• Willingness to provide informed consent for the
medical procedure;
• Capacity to understand the nature of the study and the
advice and instructions given by the healthcare
providers; and
• Woman's access to a telephone to call the service
provider and be contacted if necessary.
Study exclusion criteria, which are standard for provision
of medical abortion, included:
• Previous allergic reaction to either mifepristone or
misoprostol;Felsher Obstetric Points are not equipped with ultrasound equipment,
use of ultrasound was not a study objective. A total of 223 of 554
en applied for abortion with ultrasound results in hand; 226 of the
ining 331 women were referred for ultrasound to confirm gestational
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adnexal mass;
• Long-term corticosteroid therapy;
• Hemorrhagic disorder or anticoagulant therapy (blood
thinner medications);
• Intrauterine device in utero that could not be removed
before taking mifepristone;
• Unwilling or unable to return to clinic for follow-up visit.
Breastfeeding is not a contraindication for medical
abortion as there is no evidence that infants are harmed by
the drugs. However, although the drugs are rapidly
metabolized, they may enter breast milk in small amounts
[16]. Therefore, service providers advised women to discard
any breast milk produced in the hours following each dose of
medication.
2.4. Study enrolment
All women requesting medical abortion had their data
recorded by the midwife/nurse on a recruitment log and a
specially designed, coded participant management form.
Women requesting and eligible for medical abortion took the
mifepristone pill at the clinic and chose between either
receiving misoprostol to take at home 24–48 h later or
returning to the clinic after 24–48 h to take it. Women using
misoprostol in the clinic were given the option of remaining
there for a 4–6-h observation period or returning home to
expel the products of conception. All women took
misoprostol sublingually. All women received a nonsteroidal
anti-inflammatory drug such as ibuprofen or diclofenac for
pain medication.
2.5. Follow-up visit
All midwives received a mobile phone and/or mobile
phone credits to ensure that they could contact and be
contacted by women who received the service. All women
were asked to return for follow-up with the midwife/nurse
between 7 and 14 days following the abortion. During the
follow-up visit, the midwife/nurse confirmed the abortion
outcome through an interview with the woman (specifically
asking if she had seen the products of conception) and
administration of a urine-based pregnancy test. She also
provided the woman's choice of contraceptive method
during the follow-up visit. Service providers not trained in
IUD insertion referred women wanting an IUD to the
supervising gynecologist.
Midwives who suspected incomplete abortion could call
the gynecologist supervisor and/or make a referral. Women
with incomplete abortion were offered repeat dosing with
misoprostol or manual vacuum aspiration (MVA). Women
with ongoing pregnancies received an MVA.3 Ectopic pregnancy was ruled out through interview, general
examination including vaginal examination and ultrasound for any
suspected cases.When follow-up was completed, women were invited to
complete the questionnaire about their abortion experience,
either in the clinic or at home, place the completed form in a
sealed envelope and deposit it in a designated box for
monthly collection by the study supervisor. Midwives/nurses
provided clarifying information about the form only when
requested by the woman. The form included the following
statements/questions, framed with agree–disagree or yes–no
response options:
• The method was clearly explained to me before I took
the tablets. (agree/disagree/not sure)
• It is convenient and easy for me to get medical abortion
care from a midwife at a nearby clinic. (agree/disagree/
not sure)
• Did you receive sufficient information from
your midwife to decide which contraceptive to use?
(No/Yes/Did not want or need a contraceptive)
• If a friend needed an abortion, would you recommend
she also come to a midwife? (No/Yes/Not sure)2.6. Monitoring and supervision
The attending midwife/nurse completed all case reporting
forms. Each district had two supervisors. These women
made monthly visits to each service delivery point to
cross-check and collect the data management forms, answer
questions and discuss a range of service delivery issues. All
study forms were cross-checked twice in the field, once by
the supervisor and once by the Bishkek-based project
coordinator, prior to being submitted to the data manager
for data entry. The principal investigator, co-investigators
and on one occasion the technical lead from WHO
headquarters made periodic monitoring visits to interview
selected midwives/nurses about their experiences, answer
questions about particular cases and the data collection
process, and provide general troubleshooting.2.7. Data management
The data manager reviewed all study forms prior to data
entry into the web-based data management system Open-
Clinica (https://www.openclinica.com/) Copies were
retained by the field sites and the original kept by the data
manager in Bishkek. PDFs of the data forms were made and
sent to WHO headquarters. The WHO data analyst generated
queries and resolved all data-entry questions with her
counterpart in Kyrgyzstan. The former technical lead of the
Statistics and Information Systems unit in the WHO
Department of Reproductive Health and Research conducted
the data analysis.
Data analysis involved producing descriptive statistics for
all questions on the participant management form and
selected questions from the acceptability form. All data were
stratified and presented by study district.
able 2
onsultations with supervisor, unscheduled patient visits following
ifepristone, referrals
haracteristic Alamudun Suzak Total
idwife consultations with
supervisor (%)
13 (5.9%) 11 (3.3%) 24 (4.3%)
nscheduled visits (%) 8 (3.6%) 11 (3.3%) 19 (3.4%)
eferrals following
unscheduled visit (%)
5 (62.5%) 9 (81.8%) 14 (73.7%)
onsultations at the time
of follow-up (%)
5 (2.3%) 2 (0.4%) 7 (1.3%)
eferrals at follow-up visit (%) 5 (2.3%) 0 5 (0.9%)
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3.1. Study recruitment and participant characteristics
During the study period, 749women presented to amidwife/
nurse for an abortion. A total of 554 women were recruited into
the study — 220 women in Alamudun and 334 in Suzak.
Approximately one-quarter of the remainder did not meet the
inclusion criteria for medical abortion listed in Section 2.3,
almost all because they were beyond the gestational age limit.
Almost half of the rest preferred to have vacuum aspiration
instead of medical abortion, 13% preferred to receive medical
abortion from a gynecologist, 5% decided to continue the
pregnancy, and 3% were not pregnant (See Table 1).
No women were lost to follow-up. Midwives/nurses
conducted follow-up in person with all but one woman, who
was interviewed by telephone.
The mean age of study participants was 31 years, with a
range between 17 and 47 years. The mean number of
previous pregnancies was 3.8. The mean gestational age of
the index pregnancy was 42 days. Two-thirds (66%) of
women sought medical abortion from a midwife/nurse at a
FOP and the remaining one-third from a midwife/nurse at a
referral center.3.2. Procedure outcomes
Of the 554 participating women, 97.8% had a complete
abortion (215 or 97.7% in Alamudun and 327 or 97.9% in
Suzak), 1.8% had an incomplete abortion, and 0.4% (2 women)
had ongoing pregnancy. Both ongoing pregnancies were
investigated. In one case, the woman vomited within 10 min
of taking mifepristone and again 10 min after taking
misoprostol. She later experienced a small amount of bleeding
and called the midwife to report that she had expelled the
pregnancy; 12 days later, she had an ultrasound that confirmed
she was still pregnant with twins. She was offered vacuum
aspiration but decided instead to keep the pregnancy. In the
second case, the woman had not expelled the pregnancy 2 days
after taking misoprostol. She was offered a repeat dose of
misoprostol but declined and requested MVA.Table 1
Study recruitment data, participant age, pregnancy duration, location of
service delivery
Characteristic Alamudun Suzak Total
Women requesting abortion 246 503 749
Women recruited into the study 220 334 554
Mean age (SD) 29.0 (5.6) 31.9 (6.5) 30.7 (6.3)
Mean number of previous
pregnancies (SD)
3.45 (2.0) 4.09 (1.8) 3.84 (1.9)
Mean gestational age in days (SD) 42.6 (9.4) 41.2 (7.3) 41.8 (8.2)
Procedures managed at FOPs 145 (66%) 222 (67%) 367 (66%)










The majority of women (62%) took mifepristone in the
clinic and misoprostol at home; many women reported that it
was more private and comfortable to have the abortion at home.
Midwives consulted their gynecologist supervisors in less than
5% of cases at three stages of the process— before mifepristone
(6 cases or 1.1%), betweenmifepristone andmisoprostol (6 cases
or 1.1.%), and aftermisoprostol (12 cases or 2.2.%) (SeeTable 2).
Only 3% of participants made an unscheduled visit to
their midwife following use of mifepristone and misoprostol.
The most common reason for an unscheduled visit was
perceived excessive bleeding (11 cases). Other reasons
included the following: more pain than expected (5 cases);
less bleeding than expected, vaginal discharge, nausea/vomiting,
chills/shivering (2 cases each); and fever more than 38C (1 case).
Midwives/nurses sent 14 of the 19 women making unscheduled
visits to a referral center for further follow-up.
At the follow-up visit, seven cases led to telephone
consultation with the supervisors. Five of these consultations
reflected concerns midwives/nurses had about whether the
abortions were complete, and the women were referred for
further care. Two cases were resolved without referral.3.4. Postabortion contraception
All but 3 of the 554 women chose a contraceptive method
following their abortion — 304 (54.9%) chose pills, 148
(26.7%) condoms, 86 (15.5%) IUD, 12 (2.2%) Depo-Provera®
and 1 (0.2%) withdrawal.3.5. Women's acceptability of medical abortion services
Approximately 61% of the women (337/554) receiving
services completed the voluntary, self-administered
acceptability form at the follow-up visit. Nearly all of them
agreed that the medical abortion procedure had been clearly
explained (99.7%; 336/337 respondents), that the service
was convenient (99.4%; 334/336 respondents) and that they
would recommend the service to a friend (99.1%; 331/334
respondents). Most women also agreed that they received
sufficient information from the midwife to decide which
contraceptive to use (97.3%; 326/335 respondents).
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This study provides important evidence of the feasibility
of expanding medical abortion care to underserved women in
Kyrgyzstan by training midlevel healthcare providers.
Women receiving Medabon® from midwives or family
nurses had a high level of complete abortion and reported
satisfaction with all aspects of the services provided. There
were no adverse events or safety issues documented during
the course of the intervention. The study also demonstrated
successful home-based use of misoprostol, and a successful
and practical model for supervision and referrals.
The results are bolstered by the successful follow-up of all
554 women receiving Medabon®. Reasons for the excellent
follow-up may include one or more of the following aspects.
First, the midwives and family nurses are an integral part of
the communities where they work and are known to most of
their clients and patients, whose care they trusted. Secondly,
the study provided funds for paid mobile phone calls, thus
facilitating communication between the women and the
midwives/nurses, which both women and midwives/nurses
made good use of. These two aspects point to the value of
providing this service at community level.
Looking to the future, the scaling up and sustainability of
midwives and nurses providing medical abortion will depend
on a number of factors. Although all services were provided
free of charge during the study, a fact which probably
affected women's and service providers' overall satisfaction,
free services may not be sustainable under the current
financial conditions in the country. Maintaining stocks of
Medabon®, contraceptives, pregnancy tests and related
supplies were also extended well beyond the norms of
practice typically found in Kyrgyzstan. The impact on
women's and healthcare providers' attitudes and perceptions
if stocks cannot be sustained should not be underestimated.
Despite these caveats, the excellent results from the study
support scaling up the training of midwives and nurses in
Kyrgyzstan to provide medical abortion in underserved areas
as a strategy for improving women's access to contraception
and safe abortion care. Success in doing so will require
strengthening the health system infrastructure and taking a
number of other important steps. Medabon® or a similar
high-quality mifepristone–misoprostol combi-pack must be
registered andmade available at an affordable public-sector price.
New, permanent regulations must be established which authorize
the provision ofmedical abortion by trainedmidwives and nurses.
The procurement and distribution system for reproductive health
technologies, including medical abortion drugs and contracep-
tives, must be strengthened to ensure that services will not be
subject to commodity stockouts. Medical abortion must be added
to preservice medical education, continuing education programs
and in-service training for midwives and nurses. Lastly, midlevel
healthcare providers must be incorporated into the district-level
coordination, supervision, monitoring and reporting of abortion
services in order to ensure their ongoing enthusiasm for service
provision and quality improvement.Acknowledgments
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